See more : Red Branch Technologies, Inc. (RBTI) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclacel Pharmaceuticals, Inc. (CYCC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclacel Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Vanstar Mining Resources Inc. (VMNGF) Income Statement Analysis – Financial Results
- Apetit Oyj (APETIT.HE) Income Statement Analysis – Financial Results
- LIV Capital Acquisition Corp. II (LIVBU) Income Statement Analysis – Financial Results
- Prismaflex International, S.A. (ALPRI.PA) Income Statement Analysis – Financial Results
- First Community Corporation PFD SER A (FCCTP) Income Statement Analysis – Financial Results
Cyclacel Pharmaceuticals, Inc. (CYCC)
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 420.00K | 0.00 | 0.00 | 0.00 | 0.00 | 150.00K | 0.00 | 843.00K | 1.94M | 1.73M | 1.08M | 69.00K | 699.00K | 686.00K | 911.00K | 877.00K | 129.00K | 387.00K | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Cost of Revenue | 0.00 | 32.00K | 43.00K | 20.00K | 20.00K | 4.33M | 32.00K | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 360.00K | 418.00K | 545.00K | 429.00K | 19.57M | 21.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 420.00K | -32.00K | -43.00K | -20.00K | -20.00K | -4.18M | -32.00K | -8.63M | -10.44M | -16.54M | -10.19M | -6.52M | 339.00K | 268.00K | 366.00K | 448.00K | -19.44M | -20.82M | 813.00K | 62.00K | 170.00K | 0.00 | 30.00K | 98.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,784.67% | 0.00% | -1,024.20% | -536.93% | -954.04% | -940.31% | -9,453.62% | 48.50% | 39.07% | 40.18% | 51.08% | -15,069.77% | -5,379.33% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 19.16M | 20.27M | 15.48M | 4.76M | 4.66M | 4.33M | 4.24M | 9.48M | 12.38M | 18.28M | 11.28M | 6.59M | 9.21M | 6.41M | 9.77M | 18.87M | 10.00K | 231.00K | 13.77M | 19.70M | 13.69M | 14.66M | 14.70M | 11.26M |
| General & Administrative | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.73M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 0.00 | 5.20M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.72M | 7.38M | 7.46M | 5.88M | 5.02M | 5.37M | 5.25M | 5.52M | 5.75M | 5.89M | 7.78M | 8.58M | 7.52M | 10.12M | 8.54M | 15.35M | 11.54M | 12.32M | 9.67M | 6.88M | 4.32M | 4.98M | 5.20M | 2.40M |
| Other Expenses | 0.00 | 1.30M | 144.00K | 891.00K | 231.00K | 682.00K | 949.00K | 0.00 | 12.13K | 0.00 | 0.00 | 0.00 | 360.00K | 6.73M | 911.00K | 8.85M | 21.11M | 0.00 | 7.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 16.73M | 16.53M | 18.30M | 34.22M | 11.54M | 12.32M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Cost & Expenses | 25.87M | 27.66M | 22.94M | 10.64M | 9.68M | 9.70M | 9.49M | 14.99M | 18.13M | 24.17M | 19.06M | 15.17M | 17.09M | 16.95M | 18.85M | 34.65M | 31.11M | 33.52M | 30.50M | 26.57M | 18.01M | 19.64M | 19.91M | 13.66M |
| Interest Income | 266.00K | 210.00K | 16.00K | 42.00K | 224.00K | 331.00K | 118.00K | 37.00K | 9.00K | 6.00K | 13.00K | 22.00K | 45.00K | 37.00K | 102.00K | 1.38M | 3.55M | 2.33M | 960.00K | 421.00K | 149.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.00K | 177.00K | 318.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 31.00K | 32.00K | 43.00K | 20.00K | 20.00K | 29.00K | 32.00K | 133.00K | 210.00K | 174.00K | 70.00K | 60.00K | 241.00K | 457.00K | 668.00K | 1.86M | 299.00K | 1.10M | 1.55M | 1.31M | 929.00K | 0.00 | 0.00 | -621.00K |
| EBITDA | -25.42M | -27.62M | -22.69M | -10.62M | -9.66M | -9.52M | -9.46M | -14.02M | -15.96M | -22.26M | -17.90M | -15.05M | -15.57M | -16.18M | -19.67M | -39.96M | -24.75M | -30.13M | -19.45M | -24.48M | -16.91M | -19.64M | -19.88M | -14.18M |
| EBITDA Ratio | -6,052.86% | 0.00% | 0.00% | 0.00% | 0.00% | -6,305.33% | 0.00% | -1,718.74% | -817.13% | -1,281.37% | -1,656.92% | -21,782.61% | -2,303.58% | -2,299.13% | -1,957.85% | -3,481.53% | -24,993.80% | -8,165.89% | -2,551.54% | -39,482.26% | -9,945.29% | 0.00% | -66,250.00% | -14,472.45% |
| Operating Income | -25.45M | -27.66M | -22.94M | -10.64M | -9.68M | -9.55M | -9.49M | -14.15M | -16.17M | -22.44M | -17.97M | -15.10M | -16.39M | -16.27M | -18.30M | -42.20M | -32.54M | -33.36M | -29.69M | -26.51M | -17.84M | -19.64M | -19.88M | -13.56M |
| Operating Income Ratio | -6,060.24% | 0.00% | 0.00% | 0.00% | 0.00% | -6,365.33% | 0.00% | -1,678.53% | -831.79% | -1,293.94% | -1,658.12% | -21,888.41% | -2,344.49% | -2,371.14% | -2,009.22% | -4,811.63% | -25,222.48% | -8,620.67% | -3,651.91% | -42,761.29% | -10,492.35% | 0.00% | -66,250.00% | -13,838.78% |
| Total Other Income/Expenses | -98.00K | 1.74M | 204.00K | 955.00K | 556.00K | 923.00K | 1.03M | 376.00K | -316.00K | -212.00K | 6.09M | -4.00K | 580.00K | 245.00K | -2.58M | -8.36M | 4.89M | 1.63M | 827.00K | 1.31M | -1.00K | 0.00 | 19.88M | 621.00K |
| Income Before Tax | -25.55M | -25.92M | -22.73M | -9.68M | -9.13M | -8.63M | -8.46M | -13.77M | -16.49M | -22.65M | -11.88M | -15.11M | -15.81M | -16.68M | -20.52M | -42.14M | -26.09M | -31.50M | -37.09M | -27.24M | -17.84M | 0.00 | 0.00 | -12.94M |
| Income Before Tax Ratio | -6,083.57% | 0.00% | 0.00% | 0.00% | 0.00% | -5,750.00% | 0.00% | -1,633.93% | -848.05% | -1,306.17% | -1,095.94% | -21,894.20% | -2,261.52% | -2,431.20% | -2,252.25% | -4,804.45% | -20,227.91% | -8,140.31% | -4,561.87% | -43,933.87% | -10,492.94% | 0.00% | 0.00% | -13,205.10% |
| Income Tax Expense | -3.00M | -4.72M | -3.85M | -1.24M | -1.30M | -1.34M | -993.00K | -1.98M | -2.14M | -3.24M | -1.67M | -1.35M | -565.00K | -657.00K | -948.00K | -1.75M | -2.04M | -2.25M | -274.00K | 13.08M | 620.00K | 19.45M | 19.51M | 0.00 |
| Net Income | -22.56M | -21.20M | -18.89M | -8.45M | -7.83M | -7.29M | -7.47M | -11.79M | -14.34M | -19.39M | -10.15M | -13.19M | -15.24M | -16.02M | -19.57M | -40.39M | -24.05M | -29.26M | -29.42M | -39.59M | -18.46M | -19.45M | -19.51M | -12.94M |
| Net Income Ratio | -5,370.24% | 0.00% | 0.00% | 0.00% | 0.00% | -4,858.67% | 0.00% | -1,398.70% | -737.76% | -1,118.05% | -936.62% | -19,110.14% | -2,180.69% | -2,335.42% | -2,148.19% | -4,605.02% | -18,645.74% | -7,560.21% | -3,618.20% | -63,851.61% | -10,857.06% | 0.00% | -65,040.00% | -13,205.10% |
| EPS | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.91K | -4.92K | -3.27K |
| EPS Diluted | -26.75 | -32.23 | -31.74 | -34.86 | -143.88 | -12.05 | -19.58 | -68.85 | -105.72 | -211.93 | -160.75 | -440.40 | -509.10 | -711.22 | -1.48K | -3.32K | -2.03K | -3.67K | -7.42K | -5.35K | -2.10K | -4.21K | -4.22K | -2.80K |
| Weighted Avg Shares Out | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 3.96K | 3.96K | 3.96K |
| Weighted Avg Shares Out (Dil) | 850.82K | 657.62K | 595.08K | 242.23K | 54.41K | 604.71K | 381.56K | 171.25K | 135.65K | 91.48K | 63.16K | 29.94K | 29.94K | 22.53K | 13.21K | 12.16K | 11.83K | 7.97K | 3.96K | 7.40K | 8.79K | 4.62K | 4.62K | 4.62K |
Weekly Summary Corporate dividends, name changes, new listings
The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune Bio (INMB)
Analysts Offer Insights on Healthcare Companies: Principia Biopharma (PRNB), Constellation Pharmaceuticals (CNST) and Protagonist Therapeutics (PTGX)
Deciphera Pharmaceuticals (DCPH) Received its Third Buy in a Row
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA - American (DBVT) and Sutro Biopharma (STRO)
The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates
Dell to sell RSA
Source: https://incomestatements.info
Category: Stock Reports